Study Details
Full Title
TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer, CDZR123C12101
Principal Investigator
Jeffrey
Shevach
Protocol Number
PRO00119024
NCT ID
NCT07190300
Phase
I
Enrollment Status
Open to Enrollment